Published ahead of print on August 2, 2007, doi:10.1164/rccm.200705-656OC
© 2007 American Thoracic Society doi: 10.1164/rccm.200705-656OC
Statin Use Reduces Decline in Lung FunctionVA Normative Aging Study1 Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts; 2 Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and 3 VA Normative Aging Study, VA Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts Correspondence and requests for reprints should be addressed to Stacey E. Alexeeff, B.Sc., Exposure, Epidemiology, and Risk Program, Harvard School of Public Health, Landmark Center West, 415, 401 Park Drive, Boston, MA 02215. E-mail: sackerma{at}hsph.harvard.edu Rationale: Decreased lung function has been linked to increased inflammation and oxidative stress. Statins have demonstrated antiinflammatory and antioxidant properties. Objectives: We investigated the effect of statin use on decline in lung function in the elderly, and whether smoking modified this effect. Methods: Our study population included 2,136 measurements on 803 elderly men from the Normative Aging Study whose lung function (FVC and FEV1) was measured two to four times between 1995 and 2005. Subjects indicated statin use and smoking history at each visit. We used mixed linear models to estimate the effects of each covariate, adjusting for subject and possible confounders.
Measurements and Main Results: For those not using statins, the estimated decline in FEV1 was 23.9 ml/year (95% confidence interval [CI], –27.8 to –20.1 ml/yr), whereas those taking statins had an estimated 10.9-ml/year decline in FEV1 (95% CI, –16.9 to –5.0 ml/yr). We also examined the effect of statins with smoking by dividing the cohort into four groups: never-smokers, longtime quitters (quit Conclusions: Our results indicate that statin use attenuates decline in lung function in the elderly, with the size of the beneficial effect modified by smoking status.
Key Words: statins • lung function • FVC • FEV1 • smoking
This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10 yr ago), recent quitters (quit < 10 yr ago), and current smokers. We found a significant three-way interaction between time since first visit, statin use, and smoking status (P < 0.001). Within each smoking category, the effect of statins was always estimated to be beneficial, but the size of the improvement in the decline rate varied among smoking groups. We found similar results for FVC decline. 
